Hepatic and extrahepatic cancers are associated with MASLD due to increased adiposity and a pro-inflammatory state, leading to elevated levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and leptin, and reduced adiponectin secretion.12 The gene discussed is TNF; the disease is metabolic dysfunction-associated steatotic liver disease.